Coloplast A/S
Coloplast delivers H1 interim report in line with guidance after a good second quarter performance

DGAP-News: Coloplast A/S

2015-05-05 / 11:48

---------------------------------------------------------------------

Coloplast delivered organic growth of 7% in the
first six months of the 2014/15 financial year, increasing revenue measured in
Danish kroner by 11% to DKK 6,748 million. 

EBIT before special items was up by 11% to DKK
2,213 million, with the EBIT margin before special items at 33%, versus 33% in
H1 2013/14. 

Coloplast continues to deliver stable growth in
all business areas and in all markets. Organic sales growth by business area
was as follows: Ostomy Care 6%, Continence Care 8%, Urology Care 5% and Wound &
Skin Care 9%. Coloplast grew its European business by 5%, Other Developed
Markets by 4% and Emerging Markets by 20%. 


Improvements achieved in the second quarter
'While the first quarter didn't quite meet our
expectations, we managed to improve our performance in the second quarter,
achieving 8% organic growth. That lifts our growth rate for the half-year
reporting period to 7%, which is in line with our guidance,' said Coloplast CEO
Lars Rasmussen. 

'We have a positive underlying business
performance, and we're delivering solid results in several of our markets and
business areas. In Europe, France and Italy delivered positive performances,
and in our Emerging Markets, China continues to produce good results,' said Mr
Rasmussen, and he continued: 'I would also like to note that our latest ostomy
care product, the SenSura Mio, is adding to our growth and that we've now
launched our latest catheter, the SpeediCath Compact Eve, in ten different
countries.' 


Paying interim dividends and maintaining
guidance for the 2014/2015 financial year 
The Board of Directors has resolved that the
company will pay an interim dividend of DKK 4.50 per share following the
release of the first-half interim report, for a total dividend pay-out of DKK
953 million. 

Based on the H1 interim report, Coloplast
continues to expect full-year organic revenue growth of 8-9% and of about
13-14% in DKK. Coloplast continues to expect the EBIT margin to be about 34%,
both at constant exchange rates and in DKK. 


For further information, click here to read the H1 Interim Report.


www.coloplast.com


PRESS CONTACT
Simon Mehl Augustesen
Senior Manager, Media Relations
+45 4911 3488
dksia@coloplast.com



INVESTOR RELATIONS
Ian Christensen
Vice President, Investor Relations
+45 4911 1301
dkisec@coloplast.com



Fi  style='font-size  style='font-size  style='font-size
nancial highlights and key  :8pt;'>6M  :8pt;'>6M  :8pt;'>Change                         
DK  :8pt;'>2014/152013/14                        span>             span>                        
--------------------------------------------------------------------------------
Re  style='font-size  style='font-size  style='font-size
venue                :8pt;'>6,7486,08011%   
                                   an>               an>                 
--------------------------------------------------------------------------------
EB  style='font-size  style='font-size  style='font-size
IT                   :8pt;'>2,2131,99711%               an>               >        
--------------------------------------------------------------------------------
                                                                                
--------------------------------------------------------------------------------
EB  style='font-size  style='font-size  style='font-size
IT margin            :8pt;'>33%33%-
                                   >                 >                          
--------------------------------------------------------------------------------



Sales           size:8pt;'>6  size:8pt;'>6  ze:8pt;'>Organ  e:8pt;'>Reporte
 performance by        M      M          ic        d growth
 business area                           
              style='font-  style='font-                                 
                     size:8pt;'>2  size:8pt;'>2                                 
                     014/15             >                                       
                        D  size:8pt;'>D                                 
                      KKm    KKm                                  
--------------------------------------------------------------------------------
Ostomy          size:8pt;'>2  size:8pt;'>2  ze:8pt;'>6%8%          ,699   ,491       pan>              n>      
--------------------------------------------------------------------------------
Continence      size:8pt;'>2  size:8pt;'>2  ze:8pt;'>8%13%          ,430   ,159       pan>             an>      
--------------------------------------------------------------------------------
Urology         size:8pt;'>6  size:8pt;'>5  ze:8pt;'>5%11%          61     94         pan>             an>      
--------------------------------------------------------------------------------
Wound & Skin    size:8pt;'>9  size:8pt;'>8  ze:8pt;'>9%15%          58     36         pan>             an>      
--------------------------------------------------------------------------------
Revenue  size:8pt;'>6  size:8pt;'>6  ze:8pt;'>7%11%   ,080       pan>             an>      
--------------------------------------------------------------------------------
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-05-05 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     Coloplast A/S  
 
 
             Denmark        
ISIN:        DK0060448595   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
353081 2015-05-05